The U.S. Food and Drug Administration has filed a motion in a U.S. court seeking documents from Indian drugmaker Ranbaxy Laboratories Ltd . The U.S. is probing whether Ranbaxy destroyed reports it was required to keep, falsified data and failed to meet quality control specifications in manufacturing the generic drugs it sells.
In a sharp departure from accepted pharmaceutical industry practices, officials at a Ranbaxy plant in northern India fabricated test data to show their pills met Food and Drug Administration standards and attempted to conceal the ruse from FDA inspectors, prosecutors charge.
Ranbaxy, the best performer on India's equity benchmark this year, fell 8 percent, or 42.15 rupees, to 490 rupees in Mumbai trading. The stock dropped as much as 9.8 percent earlier.
